- Home
- REGN vs BN Comparison
REGN vs BN Comparison
Compare REGN & BN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- BN
- Stock Information
- Founded
- REGN 1988
- BN 1997
- Country
- REGN United States
- BN Canada
- Employees
- REGN N/A
- BN N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- BN Other Consumer Services
- Sector
- REGN Health Care
- BN Consumer Discretionary
- Exchange
- REGN Nasdaq
- BN Nasdaq
- Market Cap
- REGN 110.0B
- BN 89.8B
- IPO Year
- REGN 1991
- BN N/A
- Fundamental
- Price
- REGN $700.33
- BN $58.86
- Analyst Decision
- REGN Buy
- BN Buy
- Analyst Count
- REGN 26
- BN 9
- Target Price
- REGN $996.00
- BN $61.78
- AVG Volume (30 Days)
- REGN 905.6K
- BN 1.9M
- Earning Date
- REGN 02-04-2025
- BN 02-13-2025
- Dividend Yield
- REGN 0.13%
- BN 0.61%
- EPS Growth
- REGN 10.27
- BN N/A
- EPS
- REGN 38.34
- BN 0.31
- Revenue
- REGN $14,202,000,000.00
- BN $88,735,000,000.00
- Revenue This Year
- REGN $5.20
- BN N/A
- Revenue Next Year
- REGN $6.39
- BN $14.40
- P/E Ratio
- REGN $18.27
- BN $191.00
- Revenue Growth
- REGN 8.27
- BN N/A
- 52 Week Low
- REGN $642.00
- BN $38.18
- 52 Week High
- REGN $1,211.20
- BN $62.78
- Technical
- Relative Strength Index (RSI)
- REGN 52.55
- BN 47.04
- Support Level
- REGN $655.85
- BN $57.76
- Resistance Level
- REGN $689.95
- BN $61.19
- Average True Range (ATR)
- REGN 21.25
- BN 1.25
- MACD
- REGN 2.98
- BN -0.10
- Stochastic Oscillator
- REGN 63.22
- BN 29.41
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
About BN Brookfield Corporation Limited Voting Shares
Brookfield Corp is an investment firm focused on building long-term wealth for institutions and individuals. It has three businesses Asset Management, Insurance Solutions, and Operating Businesses. it invests in real assets that form the backbone of the economy to deliver risk-adjusted returns to stakeholders. It generates the majority of its revenue from Asset Management. It has a geographic presence in the UK, the United States, Australia, Canada, Brazil, India, and other countries.